Please use this identifier to cite or link to this item: http://dspace.lamu.edu.zm:8080/handle/123456789/2898
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSialubanje, Cephas-
dc.contributor.authorKapina, Muzala-
dc.contributor.authorChewe, Orbrie-
dc.contributor.authorMatapo, Belem Blamwell-
dc.contributor.authorNgomah, Albertina Moraes-
dc.contributor.authorGianetti, Brittany-
dc.contributor.authorNgosa, William-
dc.contributor.authorKasonde, Mpanga-
dc.contributor.authorMusonda, Kunda-
dc.contributor.authorMulenga, Modest-
dc.contributor.authorC, Michelo-
dc.contributor.authorSinyange, Nyambe-
dc.contributor.authorBobo, Patricia-
dc.contributor.authorZyambo, Khozya-
dc.contributor.authorMazyanga, Lucy-
dc.contributor.authorBakyaita, Nathan-
dc.contributor.authorMukonka, Victor M-
dc.date.accessioned2023-02-06T14:59:05Z-
dc.date.available2023-02-06T14:59:05Z-
dc.date.issued2022-10-21-
dc.identifier.citationSialubanje C, Kapina M, Chewe O, et al. Effectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case–control study in Lusaka, Zambia. BMJ Open 2022;12:e066945. doi:10.1136/ bmjopen-2022-066945en_US
dc.identifier.urihttp://dx.doi. org/10.1136/bmjopen-2022- 066945-
dc.identifier.urihttp://155.0.177.102:8080/jspui//xmlui/handle/123456789/2898-
dc.descriptionThis Journal article can be found at this cite:http://dx.doi. org/10.1136/bmjopen-2022- 066945en_US
dc.description.abstractZambia experienced a major cholera outbreak in 2017–2018, with more than 5905 cases reported countrywide, predominantly from the peri-urban slums of Lusaka city. The WHO recommends the use of oral cholera vaccines (OCVs) together with traditional control measures, including health promotion, provision of safe water and improving sanitation, in cholera endemic areas and during cholera outbreaks. In response to this outbreak, the Zambian government implemented the OVC campaign and administered the Euvichol-plus vaccine in the high-risk subdistricts of Lusaka. Although OCVs have been shown to be effective in preventing cholera infection in cholera endemic and outbreak settings, the effectiveness of the Euvichol-plus vaccine has not yet been evaluated in Zambia. This study aimed to determine the effectiveness of two doses of OCV administered during the 2017/2018 vaccination campaign.en_US
dc.description.sponsorshipMinistry of Health and WHO.en_US
dc.language.isoenen_US
dc.publisherBMJen_US
dc.subjectEuvichol-plus vaccineen_US
dc.subjectcholera vaccineen_US
dc.subjectLusakaen_US
dc.subjectZambiaen_US
dc.subjectOutbreaken_US
dc.titleEffectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case– control study in Lusaka, Zambiaen_US
dc.typeArticleen_US
Appears in Collections:Internal Medicine

Files in This Item:
File Description SizeFormat 
Effectiveness_of_two_doses_of_Euvichol-plus_oral_c MMPubs.pdfModest Mulenga Cholera508.96 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.